Featured Startup: Blondin Bioscience

Cancer treatment is a frustrating waiting game at the present time.  Patients with solid tumors often undergo brutal chemotherapy cycles for weeks to months before they can get an idea (through radiologic examination) of whether their therapy has been working to shrink their tumor.  At times, the studies show the therapy is working , but at other times, the studies may show that in fact, treatment … Continue reading Featured Startup: Blondin Bioscience

GV’s Approach to Healthcare Investing: An Interview with Dr. Krishna Yeshwant

Please note:  This article was originally published on TechCrunch.com. Healthcare investments — in particular, investments in digital health — are booming, and don’t seem to be slowing down. According to CB Insights, digital health funding hit nearly $5.8 billion in venture funding last year, surpassing the previous record of $4.3 billion in 2014. One of the top venture firms, GV (previously known as Google Ventures), … Continue reading GV’s Approach to Healthcare Investing: An Interview with Dr. Krishna Yeshwant

Precision Medicine: Pros & Cons

This past week, President Obama announced a $215 million proposed genetic research plan, called the Precision Medicine Initiative.  According to the plan,  the NIH would receive $130 million towards a project to map the DNA of 1 million people, the National Cancer Institute would receive $70 million to research the genetic causes of cancer, the FDA would receive $10 million to evaluate new diagnostic drugs and devices, … Continue reading Precision Medicine: Pros & Cons